X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with AANJANEYA LIFECARE - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs DR. DATSONS LABS - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES DR. DATSONS LABS ALKEM LABORATORIES/
DR. DATSONS LABS
 
P/E (TTM) x - -10.9 - View Chart
P/BV x 7.4 0.2 4,569.2% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ALKEM LABORATORIES   DR. DATSONS LABS
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
DR. DATSONS LABS
Mar-14
ALKEM LABORATORIES/
DR. DATSONS LABS
5-Yr Chart
Click to enlarge
High Rs1,589126 1,265.1%   
Low Rs1,23231 3,987.1%   
Sales per share (Unadj.) Rs417.5133.0 313.9%  
Earnings per share (Unadj.) Rs56.30.2 37,131.3%  
Cash flow per share (Unadj.) Rs64.76.6 979.3%  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.9128.8 227.5%  
Shares outstanding (eoy) m119.5731.66 377.7%   
Bonus/Rights/Conversions -FCCB-  
Price / Sales ratio x3.40.6 574.2%   
Avg P/E ratio x25.1516.1 4.9%  
P/CF ratio (eoy) x21.811.8 184.1%  
Price / Book Value ratio x4.80.6 792.5%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,6532,477 6,807.7%   
No. of employees `000NANA-   
Total wages/salary Rs m9,17156 16,377.3%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m49,9154,211 1,185.5%  
Other income Rs m1,64579 2,090.3%   
Total revenues Rs m51,5614,289 1,202.1%   
Gross profit Rs m8,482569 1,491.8%  
Depreciation Rs m1,006204 492.1%   
Interest Rs m671430 155.9%   
Profit before tax Rs m8,45113 66,543.3%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m0-2 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,6066 26,327.9%   
Profit after tax Rs m6,7315 140,233.3%  
Gross profit margin %17.013.5 125.8%  
Effective tax rate %19.048.0 39.6%   
Net profit margin %13.50.1 11,829.1%  
BALANCE SHEET DATA
Current assets Rs m27,0626,852 395.0%   
Current liabilities Rs m15,3246,711 228.3%   
Net working cap to sales %23.53.3 702.2%  
Current ratio x1.81.0 173.0%  
Inventory Days Days67161 41.3%  
Debtors Days Days41318 13.0%  
Net fixed assets Rs m12,6103,673 343.3%   
Share capital Rs m239317 75.5%   
"Free" reserves Rs m34,4903,761 917.0%   
Net worth Rs m35,0274,078 859.0%   
Long term debt Rs m1,2121,671 72.5%   
Total assets Rs m54,38712,633 430.5%  
Interest coverage x13.61.0 1,321.2%   
Debt to equity ratio x00.4 8.4%  
Sales to assets ratio x0.90.3 275.4%   
Return on assets %13.63.4 395.2%  
Return on equity %19.20.1 16,324.8%  
Return on capital %24.97.7 323.9%  
Exports to sales %12.922.9 56.5%   
Imports to sales %3.114.3 21.6%   
Exports (fob) Rs m6,461964 670.2%   
Imports (cif) Rs m1,540602 255.9%   
Fx inflow Rs m6,563964 680.8%   
Fx outflow Rs m3,012607 496.1%   
Net fx Rs m3,552357 995.1%   
CASH FLOW
From Operations Rs m7,2591,345 539.7%  
From Investments Rs m1,864-2,256 -82.6%  
From Financial Activity Rs m-9,273-1,200 772.9%  
Net Cashflow Rs m-150-2,111 7.1%  

Share Holding

Indian Promoters % 66.9 4.5 1,476.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 0.0 -  
FIIs % 0.0 1.4 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 94.1 -  
Shareholders   68,381 20,807 328.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   ABBOTT INDIA  NATCO PHARMA  AJANTA PHARMA  PFIZER  ALEMBIC PHARMA  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 23, 2018 (Close)

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES 8-QTR ANALYSIS

COMPARE ALKEM LABORATORIES WITH

MARKET STATS